Table 1.
1st Line | # (%) | 2nd Line | # (%) |
---|---|---|---|
Sorafenib/Lenvatinib | 88 (89.8) | Nivolumab | 33 (37.5) |
Pembrolizumab | 8 (9.1) | ||
Regorafenib | 18 (20.5) | ||
Cabozantinib | 20 (22.7) | ||
Ramucirumab | 9 (10.2) | ||
Nivolumab | 10 (10.2) | Sorafenib (100%) | 10 (100) |
1st Line | # (%) | 2nd Line | # (%) |
---|---|---|---|
Sorafenib/Lenvatinib | 88 (89.8) | Nivolumab | 33 (37.5) |
Pembrolizumab | 8 (9.1) | ||
Regorafenib | 18 (20.5) | ||
Cabozantinib | 20 (22.7) | ||
Ramucirumab | 9 (10.2) | ||
Nivolumab | 10 (10.2) | Sorafenib (100%) | 10 (100) |